Treats obsessions and compulsions. ANDA 213219, held by Micro Labs. Clomipramine Hydrochloride.
As of Nov 18, 2026, ANDA 213219 (Clomipramine Hydrochloride), held by Micro Labs, was first approved by FDA on Jun 22, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clomipramine hydrochloride capsules, USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2020 | Original application | Approved | None posted |
| Clomipramine Hydrochloride25MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride50MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride75MG · capsule;oral | Clomipramine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters